Cagrilintide
✅ Long-acting amylin analog (Novo Nordisk AM833)
✅ Amylin / calcitonin receptor agonist
✅ CagriSema combination partner with semaglutide
✅ Brainstem satiety + glucagon suppression
✅ Once-weekly dosing (~159 hr half-life)
Cagrilintide bevat synthetisch peptideverbinding.
✓ Medisch beoordeeld door Morgan Ellis — Apotheekonderzoeker · 8 jaar ervaring · Laatst beoordeeld: mei 2026
Quick Answer — What is Cagrilintide?
Cagrilintide (developmental code AM833) is a 37-amino-acid long-acting synthetic amylin analog developed by Novo Nordisk. It is the lead amylin-class research peptide in current metabolic research and the partner compound in the CagriSema combination (cagrilintide + semaglutide), now in late-stage Phase 3 trials for obesity and type 2 diabetes. Plasma half-life ~159 hours enables once-weekly dosing. Supplied in 5 mg and 10 mg lyophilized vials for laboratory research use only.
📦 Elke bestelling is gedekt door onze Reshipment Assurance Policy — als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.
| Specificatie | Detail |
|---|---|
| CAS-nummer | 1415456-99-3 (cagrilintide; commonly cited) |
| Type | Long-acting synthetic amylin analog (acylated 37-amino-acid peptide; calcitonin/amylin receptor agonist; Novo Nordisk developmental code AM833) |
| Moleculair gewicht | ~4,981 Da (with C20 fatty diacid acylation and intramolecular disulfide bridge) |
| Structure | 37 amino acids based on the human amylin scaffold with substitutions that reduce amyloid-forming aggregation, an intramolecular Cys2–Cys7 disulfide bridge required for receptor binding, and a C20 fatty-diacid acyl chain attached via a γ-Glu-OEG-OEG spacer that drives strong reversible serum-albumin binding for the once-weekly half-life. C-terminus amidated. |
| Form | Lyophilized powder (white to off-white) |
| Zuiverheid | ≥99% (HPLC geverifieerd, COA op aanvraag) |
| Opslag | Lyofiliseerd: 2–8 °C (koelkast) voor werkvoorraad; −20 °C voor langdurige opslag van ongeopende flesjes. Gereconstitueerd: 2–8 °C, gebruik binnen ~30 dagen. Bescherm tegen licht. Vries de gereconstitueerde oplossing niet in en ontdooi deze niet. |
| Oplosbaarheid | Bacteriostatic water (recommended) or sterile water for shorter use windows. Acylated peptides may dissolve more slowly than smaller unmodified peptides — allow extra equilibration time. |
| Onderzoeksgebruik | Alleen voor laboratoriumonderzoek. Niet voor humaan of veterinair diagnostisch of therapeutisch gebruik. |
What Is Cagrilintide?
Cagrilintide is a long-acting synthetic analog of amylin — a 37-amino-acid pancreatic peptide hormone co-secreted with insulin from beta cells and one of the principal endogenous regulators of postprandial glucose excursion, satiety signalling, and gastric emptying. Endogenous human amylin has a short plasma half-life (~13 minutes), poor pharmacokinetics, and a strong tendency to form amyloid aggregates (the same islet amyloid that accumulates in type 2 diabetic pancreas tissue). Cagrilintide was engineered by Novo Nordisk (developmental code AM833) to overcome each of these limitations: substitutions to reduce aggregation, an intramolecular disulfide bridge preserved for receptor binding, and a C20 fatty-diacid acyl chain attached via a γ-Glu-OEG-OEG spacer that drives strong reversible binding to circulating serum albumin. The combined effect is a plasma half-life of approximately 159 hours (~6.5 days), enabling once-weekly subcutaneous research dosing.
Cagrilintide has a mature molecular weight of approximately 4,981 Da including the acyl chain and disulfide bridge. The intramolecular Cys2–Cys7 disulfide is essential for receptor binding — reduction of this bond converts the peptide into an inactive linear form. The fatty-acid tether is one carbon longer than semaglutide’s C18 acyl chain, producing the long half-life through the same albumin-binding mechanism. Cagrilintide is the most advanced compound in the renewed wave of amylin-pathway pharmacology, with the lead clinical programme being the CagriSema combination — cagrilintide 2.4 mg + semaglutide 2.4 mg weekly — that completed the REDEFINE-1 (obesity) and REDEFINE-2 (T2DM) Phase 3 trials with body-weight reductions of approximately 20–23% over 68 weeks. Cagrilintide is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as a stand-alone agent or in combination. The research-grade cagrilintide sold here is supplied uitsluitend voor laboratoriumonderzoek and is not intended for human or veterinary administration.
Mechanism of Action — Amylin Receptor Agonism Across CNS and Peripheral Sites
What makes cagrilintide pharmacologically distinctive from GLP-1 agonists is that it acts on a completely different receptor system — the amylin/calcitonin receptor family — via three principal mechanisms documented in published research:
- Amylin receptor (AMY1, AMY2, AMY3) agonism — brainstem satiety circuits — Amylin receptors are heterodimers of the calcitonin receptor (CTR) with receptor activity-modifying proteins RAMP1, RAMP2, and RAMP3, generating the AMY1, AMY2, and AMY3 receptor subtypes. The principal site of action for satiety signalling is the area postrema in the brainstem — one of the few CNS regions that lacks a blood-brain barrier, allowing direct access by circulating amylin and acylated analogs like cagrilintide. Activation of brainstem AMY receptors triggers vagal and noradrenergic projections to the hypothalamus, suppressing food intake on a per-meal timescale.
- Glucagon suppression and delayed gastric emptying — In addition to central satiety, cagrilintide reproduces amylin’s peripheral metabolic actions: glucose-dependent suppression of glucagon secretion from pancreatic alpha cells, reduction of postprandial hepatic glucose output, and pronounced delay of gastric emptying. The delayed gastric emptying reinforces satiety by extending the post-meal fullness signal and reduces the magnitude of postprandial glucose excursion. Tachyphylaxis (partial desensitisation) of gastric-emptying delay develops over weeks of continuous receptor occupancy, paralleling the GLP-1-axis pattern.
- Complementary mechanism to GLP-1 — the CagriSema rationale — The clinical rationale for combining cagrilintide with semaglutide rests on the non-overlapping mechanisms. GLP-1 agonists act predominantly on hypothalamic arcuate-nucleus POMC neurons (food-intake regulation via the central appetite system) and pancreatic beta-cells (glucose-dependent insulin secretion). Amylin agonists act predominantly on brainstem area-postrema AMY receptors (per-meal satiety reinforcement) and pancreatic alpha-cells (glucagon suppression). The two mechanisms are mechanistically additive rather than overlapping, which is why CagriSema produces body-weight effects in Phase 3 trials that approach the magnitude of triple-agonist retatrutide without going through the GIP or glucagon receptor.
The C20 fatty-diacid acylation at lysine (analogous to semaglutide’s C18 modification) drives reversible serum-albumin binding that produces the ~159-hour plasma half-life. The intramolecular Cys2–Cys7 disulfide bridge maintains the bioactive conformation required for AMY-receptor binding — researchers must avoid vigorous shaking or freeze-thaw cycles that could disrupt the disulfide. Subcutaneous administration is the standard research route and the only route used in clinical development.
Published Research Applications
Cagrilintide is used in laboratory research contexts that investigate:
- Obesitas en lichaamsgewichtregulatie — preclinical DIO (diet-induced obesity) rodent models, body-composition (DEXA/MRI), food-intake assays, energy-expenditure characterisation; canonical research peptide for the renewed amylin-pathway pharmacology programme
- Combined cagrilintide + GLP-1 (CagriSema) research — head-to-head and combination studies with semaglutide in obesity and T2DM models; mechanistic dissection of complementary vs additive vs synergistic body-weight effects (Enebo et al., Lancet 2021; CagriSema Phase 3 results)
- Type 2 diabetes preclinical research — glycaemic control, glucagon suppression, postprandial glucose excursion in high-fat-diet rodent models
- Amylin receptor pharmacology — AMY1 / AMY2 / AMY3 receptor-subtype selectivity, RAMP-dependent signalling, comparative agonist potency at calcitonin vs amylin receptors
- Brainstem satiety-circuit research — area-postrema-specific receptor activation, vagal and noradrenergic projection mapping, distinction from arcuate-nucleus GLP-1 mechanisms
- Gastric emptying and postprandial physiology research — gastric emptying time, postprandial glucose dynamics, gut-hormone-axis integration
- Comparative incretin/amylin peptide research — benchmarking against single-agonist GLP-1 (Semaglutide), dual-agonist GIP/GLP-1 (Tirzepatide), and triple-agonist GLP-1/GIP/glucagon (Retatrutide) for body-weight effect, glycaemic control, and side-effect profile.
For broader context on where cagrilintide fits within the metabolic-peptide landscape, see Semaglutide as the CagriSema combination partner, Tirzepatide as the dual-receptor comparator, and Retatrutide as the triple-receptor comparator. Browse the full onderzoekspeptiden catalogus voor gerelateerde verbindingen.
Beschikbare sterktes en concentraties
MedsBase stocks Cagrilintide in two lyophilized vial sizes calibrated to typical research protocol lengths. Each strength is available in 10-vial or 20-vial pack formats with full reconstitution guidance:
| Vulsterkte | Typical Research Use Case | Verpakkingsgroottes |
|---|---|---|
| 5 mg | Standard research strength — pilot dosing, single-cohort protocols, short-cycle titration studies | 10 of 20 flesjes |
| 10 mg | Extended-cycle protocols, multi-cohort studies, lowest per-mg cost | 10 of 20 flesjes |
Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 3 clinical doses are 2.4 mg weekly (the CagriSema arm), so research-grade vials at 5 mg or 10 mg represent multi-week supplies of clinical-equivalent dosing for in-vivo work. Cagrilintide is a comparatively scarce research peptide because of the structural complexity (disulfide bridge + acyl tether) and ongoing clinical development controls, which is reflected in the per-mg price relative to small synthetic peptides.
How It Compares — Cagrilintide vs Semaglutide
Cagrilintide and Semaglutide are the two halves of the CagriSema combination — the lead Phase 3 clinical compound in current obesity pharmacology. They act on entirely different receptor systems (amylin/calcitonin vs GLP-1) and produce mechanistically complementary effects: amylin-axis satiety reinforcement and glucagon suppression on one side, GLP-1-axis appetite regulation and glucose-dependent insulin secretion on the other.
| Criterium | Cagrilintide | Semaglutide |
|---|---|---|
| Receptor family | Amylin / calcitonin receptor family (AMY1/2/3) | GLP-1 receptor (GLP-1R) |
| Length | 37 amino acids | 31 amino acids |
| Primary CNS target | Brainstem area postrema | Hypothalamic arcuate nucleus (POMC neurons) |
| Peripheral effects | Glucagon suppression, delayed gastric emptying | Insulin secretion, glucagon suppression, gastric emptying |
| Fatty acid tether | C20 diacid + γGlu-OEG-OEG | C18 diacid + γGlu-AEEA-AEEA |
| Halfwaardetijd | ~159 hours (~6.5 days) | ~165 hours (~7 days) |
| Brand reference | Investigational (AM833; CagriSema combo) | Ozempic / Wegovy / Rybelsus |
| Body-weight effect (stand-alone) | ~10% (Phase 2 monotherapy) | ~15% (STEP trials) |
| Combined (CagriSema) | ~20–23% body-weight reduction at 2.4 mg + 2.4 mg weekly (REDEFINE-1 Phase 3) | |
For research interested in the amylin axis specifically, cagrilintide is the canonical long-acting research peptide. For research interested in maximal body-weight effect via combination pharmacology, the CagriSema model (cagrilintide + semaglutide) is the lead reference. For comparison against the receptor-stacking approach taken by single-molecule multi-agonists, see Tirzepatide (dual GLP-1/GIP) and Retatrutide (triple GLP-1/GIP/glucagon).
Opslag en Reconstituering
Voor reconstituering: store lyophilized vials refrigerated at 2–8 °C in original packaging for short-term working stock. For unopened long-term storage, freeze at −20 °C. Lyophilized cagrilintide is stable under refrigeration for up to 24 months and at −20 °C for up to 36 months. Avoid freeze-thaw cycles on the lyophilized powder. Like other disulfide-bridged peptides, cagrilintide’s receptor binding depends on the intact Cys2–Cys7 bond — handling that disrupts the disulfide will degrade activity.
Reconstitueringsprocedure: inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5 mg vial, 2.0 mL of bacteriostatic water yields a 2.5 mg/mL working concentration — 0.04 mL delivers 100 mcg; 0.1 mL delivers 250 mcg; ~1.0 mL delivers a clinical-equivalent 2.4 mg research dose. Swirl gently — do niet shake — and allow 5–10 minutes for full dissolution. Acylated peptides dissolve more slowly than smaller unmodified peptides; do not rush the step. A correctly reconstituted solution should be clear and colourless with no visible particles.
Na reconstitutie: store refrigerated at 2–8 °C and use within 30 days for optimal stability. Do not freeze the reconstituted solution — freeze-thaw cycles degrade peptide integrity and can disrupt the Cys2–Cys7 disulfide bond. Discard any vial showing cloudiness, precipitate, or discolouration.
Veelgestelde vragen
What is Cagrilintide used for in research?
Cagrilintide is used in laboratory research investigating the amylin/calcitonin receptor axis, brainstem area-postrema satiety circuits, postprandial glucose physiology, gastric emptying, obesity and body-weight regulation, type 2 diabetes preclinical models, and especially combination pharmacology with GLP-1 agonists (the CagriSema research model with semaglutide). It is the most-cited long-acting amylin analog in current metabolic-peptide research. The research-grade cagrilintide sold here is niet FDA-approved and is supplied strictly for laboratory research use only.
What is CagriSema?
CagriSema is the developmental name for the fixed-dose combination of cagrilintide + semaglutide at 2.4 mg + 2.4 mg weekly. It is Novo Nordisk’s lead Phase 3 obesity programme — the REDEFINE-1 and REDEFINE-2 trials reported body-weight reductions of approximately 20–23% over 68 weeks, putting CagriSema in the same effect-size range as triple-agonist retatrutide while taking a completely different mechanistic route (combination of two single-receptor agonists rather than a single multi-agonist molecule). Cagrilintide is the amylin half of this combination.
How is Cagrilintide different from Semaglutide?
The fundamental difference is the receptor system. Cagrilintide acts on the amylin/calcitonin receptor family (AMY1, AMY2, AMY3) with primary central effects in the brainstem area postrema. Semaglutide acts on the GLP-1 receptor with primary central effects in the hypothalamic arcuate nucleus. The two are pharmacologically complementary, not competing — their combination in CagriSema produces additive body-weight effects greater than either alone. Both are long-acting peptides with C20 / C18 fatty-acid acylation enabling once-weekly dosing.
How is Cagrilintide different from Tirzepatide?
Tirzepatide is a single molecule that activates two receptors (dual GLP-1/GIP agonist). Cagrilintide activates only the amylin/calcitonin receptor family. For research interested in body-weight magnitude beyond single-receptor GLP-1, tirzepatide takes the “receptor-stacking in one molecule” approach while CagriSema (cagrilintide + semaglutide) takes the “separate molecules in combination” approach. The two strategies have produced comparable body-weight effect sizes in their respective Phase 3 trials.
What is the typical Cagrilintide research dose?
Published preclinical and clinical research protocols use weekly subcutaneous dosing with a titration schedule starting at 0.16 mg and increasing through 0.3, 0.6, 1.2, and finally 2.4 mg maintenance weekly — the same dose used in the CagriSema combination. A 5 mg vial reconstituted with 2.0 mL bacteriostatic water yields 2.5 mg/mL — approximately 1.0 mL equals a 2.4 mg clinical-equivalent research dose.
Is Cagrilintide FDA approved?
No. Cagrilintide is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as either a stand-alone agent or in the CagriSema combination. CagriSema Phase 3 trials (REDEFINE-1 obesity, REDEFINE-2 T2DM) have reported positive results but regulatory submission and review remain ongoing as of current literature. All cagrilintide sold by research-use-only suppliers is for laboratory investigation and should not be administered to humans.
How should Cagrilintide be stored?
Lyophilized vials: refrigerated at 2–8 °C for short-term working stock, or −20 °C for long-term storage of unopened vials. Reconstituted solution: refrigerated at 2–8 °C, use within 30 days. Do not freeze reconstituted solution — freeze-thaw cycles degrade the peptide and can disrupt the essential Cys2–Cys7 disulfide bridge. Protect from direct light at all times.
How do I reconstitute Cagrilintide?
Follow the reconstitution procedure above. Add bacteriostatic water down the side wall of the vial (not onto the lyophilized cake), swirl gently, and allow 5–10 minutes for full dissolution (acylated peptides dissolve more slowly than smaller unmodified peptides). Do niet shake the vial. A correctly reconstituted solution is clear and colourless with no visible particles. For a 5 mg vial + 2.0 mL diluent, the working concentration is 2.5 mg/mL.
Welke sterktes heeft MedsBase op voorraad?
MedsBase carries Cagrilintide in 5 mg and 10 mg lyophilized vials. Each strength is available in 10-vial or 20-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request.
Why is Cagrilintide more expensive than other peptides?
Cagrilintide is structurally complex (37 amino acids with an intramolecular disulfide bridge and a fatty-diacid acyl chain) and is a relatively recent compound still under active clinical development by Novo Nordisk. Both factors contribute to higher synthesis cost and constrained supply relative to mature small synthetic peptides like BPC-157 or TB-500. The per-mg price reflects these supply-and-complexity factors rather than any difference in research utility.
Can Cagrilintide be paired with Semaglutide in research?
Yes — this is the canonical CagriSema research protocol and the lead Phase 3 clinical combination. Cagrilintide and semaglutide act on different receptor families (amylin/calcitonin vs GLP-1) with non-overlapping central and peripheral mechanisms, producing additive body-weight effects substantially greater than either alone. The clinical fixed-dose ratio is 2.4 mg cagrilintide + 2.4 mg semaglutide weekly.
Does Cagrilintide cause side effects in research?
Like other satiety-axis peptides, the most consistent finding is gastrointestinal — nausea, transient appetite suppression, and delayed gastric emptying are dose-dependent and tend to attenuate over 4–8 weeks of continuous dosing as receptor tachyphylaxis develops. Because cagrilintide is the amylin analog and not a GLP-1, the gastrointestinal profile differs from semaglutide in pattern, but the magnitude is comparable in published clinical research. Long-term safety data continues to accumulate from Phase 3 trials.
What is the half-life of Cagrilintide?
Cagrilintide has a plasma half-life of approximately 159 hours (~6.5 days) following subcutaneous administration. The extended half-life is achieved by reversible binding to circulating serum albumin via the C20 fatty-diacid tether at lysine, which protects the peptide from renal clearance. The half-life is comparable to semaglutide’s ~165 hours, allowing both compounds to be co-dosed weekly in CagriSema research without divergent pharmacokinetics.
How long does Cagrilintide take to show effects in preclinical research?
Acute pharmacodynamic effects on gastric emptying and per-meal satiety are detectable within hours of the first dose. Body-weight effects in DIO rodent models typically become statistically significant after 1–2 weeks of weekly dosing and continue to accrue through 8–12 weeks. Maximum effect on body composition develops over 16–24 weeks of continuous dosing, mirroring the human Phase 3 trajectory in REDEFINE-1.
Can I order Cagrilintide for international shipping?
Yes. MedsBase ships Cagrilintide worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our Reshipment Assurance Policy.
Other Peptides for Metabolic, Body-Composition, and Satiety-Axis Research
- Semaglutide — Single GLP-1 agonist — CagriSema combination partner; canonical glycaemic and CV-research comparator
- Tirzepatide — Dual GLP-1/GIP agonist — receptor-stacking-in-one-molecule comparator
- Retatrutide — Triple GLP-1/GIP/glucagon agonist — multi-axis metabolic research
- MOTS-c — Mitochondrially-encoded peptide — AMPK and insulin-sensitivity research
- Tesamorelin — GHRH analog — visceral adiposity research
Verder lezen
📖 Explore the metabolic-peptide combination landscape
Bekijk het volledige onderzoekspeptiden catalogus, with related metabolic-peptide compounds including Semaglutide (CagriSema partner), Tirzepatide (dual GLP-1/GIP comparator), and Retatrutide (triple-agonist comparator). Head-to-head guide: Retatrutide vs Tirzepatide — triple vs dual agonist.
Meer opties in Peptiden
Gerangschikt op recente bestelvolumes van MedsBase — wat andere klanten in deze categorie kiezen.
| Sterkte | 5 mg, 10 mg |
|---|---|
| Hoeveelheid | 10 flacons, 20 flacons, 30 flacons |
Cagrilintide
Vragen & antwoorden
Cagrilintide
Gerelateerde producten
Beoordelingen
Er zijn nog geen beoordelingen